Master diabetes mellitus for NEET PG 2026: classification (Type 1, Type 2, GDM, MODY), diagnostic criteria, complications, insulin regimens, oral hypoglycemics, DKA vs HHS, and management in special populations.
Version 1.0 — Published March 2026
Diabetes mellitus contributes 3–5 direct questions per NEET PG paper. Master these 10 high-yield areas:
Diabetes mellitus is a group of metabolic disorders characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. It is the single most tested endocrinology topic in NEET PG, appearing not just in medicine but crossing into pharmacology (oral hypoglycemics), obstetrics (gestational diabetes), ophthalmology (diabetic retinopathy), and surgery (diabetic foot). The student who masters DM classification, diagnostic criteria, and emergency management has covered the foundation for at least 3–5 marks across multiple papers.
This guide covers every testable aspect of diabetes — from the molecular pathophysiology that explains clinical features to the drug tables and emergency protocols that NBE tests as standalone questions. Pair this with daily MCQ practice on the Medicine subject hub and cross-reference the high-yield medicine topics overview for context on how diabetes fits into the broader endocrinology testing pattern.
This content is for educational purposes for NEET PG exam preparation. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical information has been reviewed by qualified medical professionals.
Start practicing NEET PG MCQs with AI-powered explanations.
Start Free PracticeAvoid the 10 costliest medicine mistakes in NEET PG 2026: confused anemia types, wrong hepatitis serology, diabetes diagnostic errors, thyroid function mix-ups, murmur misidentification, antibiotic selection errors, nephrotic vs nephritic confusion, acid-base disorders, ABG misinterpretation, and autoimmune marker confusion.
How AI supercharges spaced repetition for NEET PG — the neuroscience of memory, Ebbinghaus forgetting curve, adaptive scheduling, and practical implementation. Compare Anki, NEETPGAI, and manual flashcards.
An unbiased feature-by-feature comparison of NEETPGAI and Marrow for NEET PG 2026. Covers QBank, video lectures, pricing, AI features, mock tests, and which platform suits your preparation style.
Daily MCQs, study tips, and topper strategies on Telegram.
Join on Telegram →Diabetes classification is the systematic categorization of diabetes subtypes based on etiology and pathophysiology — and it forms the foundation for every clinical question on DM in NEET PG.
Type 1 DM is autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency. It accounts for 5–10% of all diabetes cases and typically presents in childhood or adolescence, though adult-onset Type 1 (LADA — Latent Autoimmune Diabetes in Adults) is increasingly recognized.
Key features tested by NBE:
Type 2 DM is a combination of insulin resistance and progressive beta-cell dysfunction — responsible for 90% of diabetes globally and the vast majority of questions in NEET PG.
Pathophysiology (the "ominous octet" — DeFronzo):
Risk factors: Obesity (BMI >=25 in Asians), family history, sedentary lifestyle, polycystic ovary syndrome, history of GDM, impaired glucose tolerance.
GDM is glucose intolerance with onset or first recognition during pregnancy. It affects 7–14% of pregnancies in India (higher than the global average of 6–9%).
Screening: Universal screening at 24–28 weeks. DIPSI (Diabetes in Pregnancy Study Group of India) recommends a single-step 75g OGTT with a 2-hour glucose cutoff of >=140 mg/dL.
Risk to the fetus: Macrosomia, neonatal hypoglycemia, respiratory distress syndrome, shoulder dystocia, increased risk of childhood obesity and Type 2 DM later in life.
MODY is a monogenic form of diabetes with autosomal dominant inheritance, presenting before age 25 in a non-obese individual with a strong family history spanning three generations.
| MODY Type | Gene | Clinical feature | Treatment |
|---|---|---|---|
| MODY 1 | HNF-4 alpha | Progressive hyperglycemia, macrosomia at birth | Sulfonylureas |
| MODY 2 | Glucokinase | Mild fasting hyperglycemia (5.5–8 mmol/L), stable, rarely needs treatment | Diet alone (usually) |
| MODY 3 | HNF-1 alpha | Most common MODY, progressive, glycosuria at low glucose threshold | Sulfonylureas (very sensitive) |
| MODY 5 | HNF-1 beta | Renal cysts + diabetes (renal cysts and diabetes syndrome) | Insulin |
NBE exam point: MODY 3 is the most common type overall. MODY 2 is the mildest and often diagnosed incidentally. The key differentiator from Type 1 is: autosomal dominant family history, absence of autoantibodies, and detectable C-peptide.
Diagnostic criteria for diabetes are the laboratory thresholds established by ADA and WHO to confirm hyperglycemia — and these exact numbers are tested repeatedly in NEET PG.
| Test | Normal | Prediabetes | Diabetes |
|---|---|---|---|
| Fasting plasma glucose | <100 mg/dL | 100–125 mg/dL (IFG) | >=126 mg/dL |
| 2-hour OGTT (75g) | <140 mg/dL | 140–199 mg/dL (IGT) | >=200 mg/dL |
| HbA1c | <5.7% | 5.7–6.4% | >=6.5% |
| Random plasma glucose | — | — | >=200 mg/dL + symptoms |
Rules for confirmation:
GDM diagnostic criteria (IADPSG/WHO 2013): 75g OGTT — fasting >=92 mg/dL, 1-hour >=180 mg/dL, or 2-hour >=153 mg/dL. Any ONE abnormal value confirms GDM.
Diabetic complications are the end-organ damage resulting from chronic hyperglycemia — categorized into microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (CAD, stroke, PVD) based on the vessel size affected.
Diabetic retinopathy — the leading cause of blindness in adults aged 20–74 years:
| Stage | Findings | Management |
|---|---|---|
| Mild NPDR | Microaneurysms only | Annual screening |
| Moderate NPDR | Microaneurysms + dot/blot hemorrhages + hard exudates + cotton wool spots | 6-monthly screening |
| Severe NPDR | 4-2-1 rule: hemorrhages in 4 quadrants, venous beading in 2 quadrants, IRMA in 1 quadrant | Consider panretinal photocoagulation |
| Proliferative DR | Neovascularization (disc or elsewhere), vitreous hemorrhage, tractional RD | Panretinal laser photocoagulation, anti-VEGF |
| Diabetic macular edema | Macular thickening, hard exudates at macula | Anti-VEGF intravitreal injection (first-line) |
NBE trap: The 4-2-1 rule defines SEVERE NPDR, not proliferative. Neovascularization is the hallmark of proliferative retinopathy.
Diabetic nephropathy — the leading cause of end-stage renal disease worldwide:
Diabetic neuropathy — the most common complication of diabetes:
Cardiovascular disease is the leading cause of death in Type 2 diabetes. The risk is 2–4 times higher than in non-diabetic individuals.
Master NEET PG with AI-powered practice — 50,000+ MCQs with instant explanations.
Start Free Practice →Insulin therapy is the exogenous replacement of endogenous insulin — mandatory in Type 1 and required in advanced Type 2 when oral agents fail to achieve glycemic targets.
| Insulin type | Examples | Onset | Peak | Duration | Clinical use |
|---|---|---|---|---|---|
| Rapid-acting | Lispro, Aspart, Glulisine | 10–15 min | 1–2 hr | 3–5 hr | Pre-meal bolus |
| Short-acting | Regular (soluble) | 30 min | 2–4 hr | 6–8 hr | Pre-meal, DKA IV infusion |
| Intermediate | NPH (isophane) | 1–2 hr | 4–12 hr | 12–18 hr | Basal (twice daily) |
| Long-acting | Glargine, Detemir | 1–2 hr | Peakless | 20–24 hr | Basal (once daily) |
| Ultra-long | Degludec | 30–90 min | Peakless | >42 hr | Basal (flexible timing) |
| Premixed | 70/30 (NPH/Regular) | 30 min | Dual | 12–18 hr | Simplified regimen |
Basal-bolus regimen: Long-acting (once daily) + rapid-acting before each meal. This is the physiologic replacement that best mimics normal insulin secretion. Most commonly tested regimen in NEET PG.
Key NBE points:
Oral hypoglycemics are non-insulin pharmacological agents used to manage Type 2 diabetes — and their classification, mechanism, and adverse effects constitute one of the most heavily tested pharmacology topics in NEET PG.
| Drug class | Mechanism | Key ADR | Weight effect | Hypoglycemia risk |
|---|---|---|---|---|
| Biguanides (metformin) | Decreases hepatic gluconeogenesis, increases insulin sensitivity | Lactic acidosis (rare), GI upset, B12 deficiency | Neutral/loss | No |
| Sulfonylureas (glimepiride, gliclazide) | Stimulates insulin secretion via K-ATP channel closure | Hypoglycemia, weight gain | Gain | Yes |
| Meglitinides (repaglinide, nateglinide) | Short-acting insulin secretagogue (same channel, different site) | Hypoglycemia | Gain | Yes |
| Thiazolidinediones (pioglitazone) | PPAR-gamma agonist, increases insulin sensitivity | Fluid retention, weight gain, fractures, bladder cancer risk | Gain | No |
| DPP-4 inhibitors (sitagliptin, vildagliptin) | Inhibits incretin degradation, increases GLP-1 | Nasopharyngitis, pancreatitis (rare) | Neutral | No |
| GLP-1 agonists (liraglutide, semaglutide) | Incretin mimetic, increases insulin, decreases glucagon | Nausea, pancreatitis (rare), medullary thyroid cancer (rodent data) | Loss | No |
| SGLT2 inhibitors (empagliflozin, dapagliflozin) | Inhibits glucose reabsorption in proximal tubule | UTI, genital mycotic infections, euglycemic DKA, Fournier gangrene | Loss | No |
| Alpha-glucosidase inhibitors (acarbose, voglibose) | Delays carbohydrate absorption | Flatulence, diarrhea | Neutral | No |
First-line: Metformin (unless contraindicated — eGFR <30, metabolic acidosis, hepatic failure, contrast dye administration)
SGLT2 inhibitors — the new high-yield area:
Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) are the two acute metabolic emergencies of diabetes — and their comparison is one of the most predictable NEET PG questions.
| Feature | DKA | HHS |
|---|---|---|
| Typical patient | Type 1 (or Type 2 in severe stress) | Type 2 (elderly, often newly diagnosed) |
| Blood glucose | 250–600 mg/dL | >600 mg/dL (often >1000) |
| Arterial pH | <7.3 | >7.3 |
| Serum bicarbonate | <18 mEq/L | >18 mEq/L |
| Serum ketones | Strongly positive | Absent or trace |
| Anion gap | Elevated (>12) | Normal or mildly elevated |
| Serum osmolality | Variable (usually <320) | >320 mOsm/kg |
| Mental status | Alert to obtunded | Stupor to coma |
| Dehydration | Moderate (3–6 L deficit) | Severe (8–10 L deficit) |
| Kussmaul breathing | Present | Absent |
| Mortality | <5% with treatment | 10–20% (higher) |
Resolution criteria: Glucose <200 mg/dL AND at least two of: bicarbonate >=15, venous pH >7.3, anion gap <=12.
Same principles as DKA but with key differences:
Hypoglycemia is defined as blood glucose <70 mg/dL (ADA) — the most common acute complication of insulin therapy and sulfonylurea use, and a frequent NEET PG question.
Whipple triad (defines true hypoglycemia):
Classification:
Management:
Glycemic monitoring is the systematic tracking of blood glucose and HbA1c to guide therapy — with target values that vary by patient population.
| Parameter | General target | Elderly/comorbid | Pregnancy |
|---|---|---|---|
| HbA1c | <7.0% | <8.0% | <6.0% (Type 1/2), <6.5% (GDM) |
| Fasting glucose | 80–130 mg/dL | 100–180 mg/dL | <95 mg/dL |
| Postprandial (2-hr) | <180 mg/dL | <200 mg/dL | <120 mg/dL |
| Pre-meal | 80–130 mg/dL | 100–150 mg/dL | <95 mg/dL |
HbA1c reflects the average blood glucose over the preceding 8–12 weeks (red blood cell lifespan). A 1% decrease in HbA1c reduces microvascular complications by approximately 37% (UKPDS) and MI risk by 14%.
Continuous glucose monitoring (CGM): Measures interstitial glucose every 5 minutes. Time in range (TIR) of 70–180 mg/dL for >70% of the day correlates with HbA1c <7%. Increasingly tested in recent NEET PG papers.
Pre-gestational diabetes (Type 1 or Type 2 entering pregnancy):
Gestational diabetes management:
| eGFR (mL/min) | Drug adjustment |
|---|---|
| >45 | All drugs can be used |
| 30–45 | Reduce metformin dose by 50%, avoid glyburide (active metabolites) |
| 15–30 | Stop metformin, SGLT2 inhibitors for renal protection only (not glucose lowering), insulin dose often DECREASES (reduced renal clearance) |
| <15 / dialysis | Insulin is the primary agent, dose decreases by 25–50% |
NBE trap: Insulin requirements DECREASE in advanced CKD — the kidneys normally clear 30–80% of circulating insulin. As renal function declines, insulin accumulates. Do not increase insulin dose in a diabetic patient with worsening kidney function who develops recurrent hypoglycemia.
Diabetes mellitus contributes 3-5 direct questions per NEET PG paper across medicine, pharmacology, and obstetrics. DKA vs HHS differentiation, insulin types, and oral hypoglycemic mechanisms are the three most frequently tested subtopics based on 2019-2025 pattern analysis.
HbA1c of 6.5% or higher on two separate occasions confirms diabetes (ADA 2024). Values of 5.7-6.4% indicate prediabetes. HbA1c is unreliable in hemoglobinopathies, hemolytic anemias, and chronic kidney disease — use fasting plasma glucose or OGTT instead.
DKA presents with Type 1 diabetes, blood glucose 250-600 mg/dL, arterial pH below 7.3, positive serum ketones, and Kussmaul breathing. HHS presents with Type 2 diabetes, glucose often above 600 mg/dL, pH above 7.3, absent or trace ketones, and severe dehydration with altered sensorium.
Insulin degludec (ultra-long acting) has the longest duration at over 42 hours with a flat, peakless profile. Insulin glargine U-300 lasts about 36 hours. Both are used as basal insulins. Regular insulin peaks at 2-4 hours and lasts 6-8 hours — the most commonly tested insulin in NEET PG.
Metformin is the universal first-line drug for Type 2 diabetes (ADA 2024). It works by inhibiting hepatic gluconeogenesis and improving peripheral insulin sensitivity. It does not cause hypoglycemia or weight gain. Contraindicated when eGFR falls below 30 mL/min due to lactic acidosis risk.
MODY 3 (HNF-1 alpha, most common overall) and MODY 2 (glucokinase, mildest form requiring no treatment) are the two most tested types. MODY is autosomal dominant, presents before age 25, and is non-insulin-dependent initially — these three features distinguish it from Type 1 diabetes in exam vignettes.
First-line management is medical nutrition therapy and exercise. If targets are not met within 1-2 weeks, insulin is the preferred pharmacological agent. Metformin is sometimes used but crosses the placenta. Glyburide has fallen out of favor. Target: fasting glucose below 95 mg/dL, 1-hour postprandial below 140 mg/dL.
Cerebral edema is the most dangerous complication, occurring primarily in children during DKA correction. It results from rapid fluid administration and too-fast correction of hyperglycemia. Treatment is IV mannitol. Other complications include hypokalemia from insulin therapy and hypoglycemia from overtreatment.
Thiazolidinediones (pioglitazone, rosiglitazone) cause the most weight gain among oral hypoglycemics through PPAR-gamma activation and adipocyte differentiation. Sulfonylureas also cause weight gain via insulin secretion. In contrast, metformin is weight-neutral and SGLT2 inhibitors cause weight loss.
The general HbA1c target is below 7.0% for most adults (ADA 2024). More stringent targets of below 6.5% apply to newly diagnosed young patients without complications. Relaxed targets of below 8.0% are acceptable for elderly patients, those with limited life expectancy, or extensive comorbidities.
Ready to test your diabetes knowledge? The best way to convert this guide into exam marks is active recall through MCQ practice.
Explore our pricing plans for unlimited practice across all 19 subjects, AI-powered doubt resolution, and personalized study plans.
This content is for educational purposes for NEET PG exam preparation. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical information has been reviewed by qualified medical professionals.
Written by: NEETPGAI Editorial Team Reviewed by: Pending SME Review Last reviewed: March 2026
This article is reviewed by qualified medical professionals for clinical accuracy and exam relevance. For corrections or updates, contact the editorial team.